drugset / Trial / NCT06478693
A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.
Timeline
- Start
- 2024-07-01
- Primary completion
- 2027-12-31
- Completion
- 2028-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MT-303 | Unknown | — | Intravenous |
| Background | Atezolizumab | Monoclonal antibody | — | Intravenous |
| Background | Bevacizumab | Monoclonal antibody | — | Intravenous |